Table 1.
Baseline patient characteristics
| Continuous dosing cohort (n=30) | Intermittent dosing cohort (n=10) | All patients (n=40) | |
| Age, years, median (range) | 46.5 (32–64) | 39.5 (29–60) | 45.5 (29–64) |
| Prior therapy in advanced setting | |||
| No | 8 (26.7) | 2 (20.0) | 10 (25.0) |
| One line | 16 (53.3) | 4 (40.0) | 20 (50.0) |
| Two lines | 6 (20.0) | 4 (40.0) | 10 (25.0) |
| Time on prior therapy before enrollment, months, median (range) | 4.9 (0–29.3) | 5.1 (0–20.5) | 5.1 (0–29.3) |
| Metastatic disease | 28 (93.3) | 9 (90.0) | 37 (92.5) |
| No. of sites of metastatic disease* | |||
| 0–3 | 23 (76.7) | 7 (70.0) | 30 (75.0) |
| ≥4 site of metastatic disease | 7 (23.3) | 3 (30.0) | 10 (25.0) |
| Bone | 6 (20.0) | 4 (40.0) | 10 (25.0) |
| Live | 8 (26.7) | 4 (40.0) | 12 (30.0) |
| Lung | 13 (43.3) | 6 (60.0) | 19 (47.5) |
| Lymph node only | 2 (6.7) | 1 (10.0) | 3 (7.5) |
| PD-L1 IC status | |||
| Negative | 18 (60.0) | 8 (80.0) | 26 (65.0) |
| Positive | 12 (40.0) | 2 (20.0) | 14 (35.0) |
| PD-L1 TC status | |||
| Negative | 19 (63.3) | 8 (80.0) | 27 (67.5) |
| Positive | 11 (36.7) | 2 (20.0) | 13 (32.5) |
Data presented as n (%) or median (range).
*Some patients had multiple sites of metastatic disease.
IC, immune cells; TC, tumor cells.